CL2023002202A1 - Mutaciones en regiones constantes de anticuerpos caninos - Google Patents

Mutaciones en regiones constantes de anticuerpos caninos

Info

Publication number
CL2023002202A1
CL2023002202A1 CL2023002202A CL2023002202A CL2023002202A1 CL 2023002202 A1 CL2023002202 A1 CL 2023002202A1 CL 2023002202 A CL2023002202 A CL 2023002202A CL 2023002202 A CL2023002202 A CL 2023002202A CL 2023002202 A1 CL2023002202 A1 CL 2023002202A1
Authority
CL
Chile
Prior art keywords
mutations
constant regions
canine antibodies
canine
antibodies
Prior art date
Application number
CL2023002202A
Other languages
English (en)
Spanish (es)
Inventor
Marie Bergeron Lisa
Luis CAMPOS Henry
Ann Marie Lightle Sandra
Original Assignee
Zoetis Services Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zoetis Services Llc filed Critical Zoetis Services Llc
Publication of CL2023002202A1 publication Critical patent/CL2023002202A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CL2023002202A 2021-01-28 2023-07-26 Mutaciones en regiones constantes de anticuerpos caninos CL2023002202A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163142774P 2021-01-28 2021-01-28

Publications (1)

Publication Number Publication Date
CL2023002202A1 true CL2023002202A1 (es) 2024-01-12

Family

ID=80786846

Family Applications (4)

Application Number Title Priority Date Filing Date
CL2023002202A CL2023002202A1 (es) 2021-01-28 2023-07-26 Mutaciones en regiones constantes de anticuerpos caninos
CL2024001562A CL2024001562A1 (es) 2021-01-28 2024-05-24 Mutaciones en regiones constantes de anticuerpos caninos.
CL2025001754A CL2025001754A1 (es) 2021-01-28 2025-06-13 Mutaciones en regiones constantes de anticuerpos caninos.
CL2026000660A CL2026000660A1 (es) 2021-01-28 2026-03-06 Mutaciones en regiones constantes de anticuerpos caninos

Family Applications After (3)

Application Number Title Priority Date Filing Date
CL2024001562A CL2024001562A1 (es) 2021-01-28 2024-05-24 Mutaciones en regiones constantes de anticuerpos caninos.
CL2025001754A CL2025001754A1 (es) 2021-01-28 2025-06-13 Mutaciones en regiones constantes de anticuerpos caninos.
CL2026000660A CL2026000660A1 (es) 2021-01-28 2026-03-06 Mutaciones en regiones constantes de anticuerpos caninos

Country Status (15)

Country Link
US (1) US20240059777A1 (cg-RX-API-DMAC10.html)
EP (2) EP4512416A3 (cg-RX-API-DMAC10.html)
JP (1) JP2024505072A (cg-RX-API-DMAC10.html)
KR (1) KR20230136604A (cg-RX-API-DMAC10.html)
CN (1) CN116802205A (cg-RX-API-DMAC10.html)
AU (1) AU2022214843A1 (cg-RX-API-DMAC10.html)
CA (1) CA3207285A1 (cg-RX-API-DMAC10.html)
CL (4) CL2023002202A1 (cg-RX-API-DMAC10.html)
CO (1) CO2023009994A2 (cg-RX-API-DMAC10.html)
EC (1) ECSP23057156A (cg-RX-API-DMAC10.html)
IL (1) IL304522A (cg-RX-API-DMAC10.html)
MX (1) MX2023008785A (cg-RX-API-DMAC10.html)
PE (1) PE20231919A1 (cg-RX-API-DMAC10.html)
TW (1) TW202246318A (cg-RX-API-DMAC10.html)
WO (1) WO2022165067A2 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL297287A (en) * 2020-04-17 2022-12-01 Zoetis Services Llc Canine antibody variants
MX2023008785A (es) 2021-01-28 2023-12-14 Zoetis Services Llc Mutaciones en regiones constantes de anticuerpos caninos.
AU2023334358A1 (en) * 2022-09-02 2025-03-13 Zoetis Services Llc Porcine antibody mutants
WO2026125320A1 (en) * 2024-12-10 2026-06-18 Intervet International B.V. Caninized il31rα antibodies with an extended half life
WO2026125322A1 (en) * 2024-12-10 2026-06-18 Intervet International B.V. CANINIZED IL31Rα ANTIBODIES WITH AN EXTENDED HALF LIFE
WO2026125321A1 (en) * 2024-12-10 2026-06-18 Intervet International B.V. Caninized il31rα antibodies with an extended half life
CN121574951B (zh) * 2026-01-27 2026-04-28 金发科技股份有限公司 一种苹果酸脱氢酶、含有其的工程化库德里亚兹毕赤酵母及其应用

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6284471B1 (en) 1991-03-18 2001-09-04 New York University Medical Center Anti-TNFa antibodies and assays employing anti-TNFa antibodies
US5698762A (en) 1994-12-09 1997-12-16 Dauerman; Leonard Microwave-assisted pyrolysis of waste polyaromatic hydrocarbons
US20030031671A1 (en) 2001-08-01 2003-02-13 Sydney Welt Methods of treating colon cancer utilizing tumor-specific antibodies
CA2577133A1 (en) 2004-08-19 2006-03-23 Genentech, Inc. Polypeptide variants with altered effector function
US9200079B2 (en) 2004-11-12 2015-12-01 Xencor, Inc. Fc variants with altered binding to FcRn
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8546543B2 (en) 2004-11-12 2013-10-01 Xencor, Inc. Fc variants that extend antibody half-life
US8790651B2 (en) 2011-07-21 2014-07-29 Zoetis Llc Interleukin-31 monoclonal antibody
EP3526246A1 (en) * 2016-10-17 2019-08-21 Vetoquinol SA Modified antibody constant region
EP3866842A4 (en) * 2018-10-18 2022-07-13 Kindred Biosciences, Inc. FC VARIANTS WITH MODIFIED BINDING TO THE NEONATAL FC RECEPTOR (FCRN) FOR VETERINARY USE
CN120005022A (zh) * 2019-01-03 2025-05-16 因外泰克斯公司 用于增加治疗剂在犬中的半衰期的组合物及使用方法
MX2023008785A (es) 2021-01-28 2023-12-14 Zoetis Services Llc Mutaciones en regiones constantes de anticuerpos caninos.

Also Published As

Publication number Publication date
CL2025001754A1 (es) 2026-04-17
MX2023008785A (es) 2023-12-14
CL2024001562A1 (es) 2024-08-23
AU2022214843A9 (en) 2024-05-16
EP4512416A2 (en) 2025-02-26
CO2023009994A2 (es) 2023-08-09
CN116802205A (zh) 2023-09-22
AU2022214843A1 (en) 2023-07-20
CL2026000660A1 (es) 2026-06-26
US20240059777A1 (en) 2024-02-22
EP4284825A2 (en) 2023-12-06
PE20231919A1 (es) 2023-11-28
ECSP23057156A (es) 2023-08-31
CA3207285A1 (en) 2022-08-04
EP4512416A3 (en) 2025-06-18
KR20230136604A (ko) 2023-09-26
IL304522A (en) 2023-09-01
WO2022165067A3 (en) 2022-09-22
JP2024505072A (ja) 2024-02-02
WO2022165067A2 (en) 2022-08-04
TW202246318A (zh) 2022-12-01

Similar Documents

Publication Publication Date Title
CL2024001562A1 (es) Mutaciones en regiones constantes de anticuerpos caninos.
CL2023003377A1 (es) Variantes de anticuerpos caninos
CL2023003376A1 (es) Variantes de anticuerpos felinos
CL2024001519A1 (es) Mutaciones en regiones constantes de anticuerpos felinos.
ECSP23030271A (es) Variantes de anticuerpos caninos
ECSP23030307A (es) Variantes de anticuerpos felinos
CO2023007146A2 (es) Variantes de anticuerpos bovinos
JOP20200302A1 (ar) الأجسام المضادة لـ cd3 واستخداماتها
CO2019001111A2 (es) Anticuerpos nuevos que se unen específicamente a los epítopos del virus del zika y usos de los mismos
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
EA201891582A1 (ru) Иммуностимулирующие гуманизированные моноклональные антитела против интерлейкина-2 человека и их слитые белки
SA523450918B1 (ar) أجسام مضادة للنكتين-4 واستخداماتها
EP4110827A4 (en) ANTI-CD137 CONSTRUCTS, MULTISPECIFIC ANTIBODIES AND THEIR USES
CO2024007674A2 (es) Anticuerpo anti-trem2 y usos del mismo
MX2025002524A (es) Mutantes de anticuerpos equinos
EA202192532A1 (ru) Мирикизумаб для применения в способе лечения болезни крона
TR202104726A2 (tr) Köfte form maki̇nasinda yeni̇li̇k
EA201991614A1 (ru) СПЕЦИФИЧНЫЕ К ИЗОФОРМЕ, ПЕРМИССИВНЫЕ ПО ОТНОШЕНИЮ К КОНТЕКСТУ ИНГИБИТОРЫ TGFβ1 И ИХ ПРИМЕНЕНИЕ
EA201992186A1 (ru) Антитела к par2 и пути их применения
TWD200747S (zh) 髮夾